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Neurotransmitters and peptide hormones are secreted by
regulated vesicle exocytosis. CAPS (also known as CADPS) is a
145-kDa cytosolic and peripheral membrane protein required
for vesicle docking and priming steps that precede Ca2-trig-
gered vesicle exocytosis. CAPS binds phosphatidylinositol 4,5-bi-
sphosphate (PI(4,5)P2) and SNARE proteins and is proposed to
promote SNARE protein complex assembly for vesicle docking
and priming.We characterized purified soluble CAPS asmainly
monomer in equilibrium with small amounts of dimer. How-
ever, the active form of CAPS bound to PC12 cell membranes or
to liposomes containing PI(4,5)P2 and Q-SNARE proteins was
mainly dimer. CAPS dimer formation required its C2 domain
based on mutation or deletion studies. Moreover, C2 domain
mutations or deletions resulted in a loss of CAPS function in
regulated vesicle exocytosis, indicating that dimerization is
essential for CAPS function. Comparison of the CAPS C2
domain to a structurally defined Munc13-1 C2A domain dimer
revealed conserved residues involved inCAPSdimerization.We
conclude that CAPS functions as a C2 domain-mediated dimer
in regulated vesicle exocytosis. The unique tandem C2-PH
domain of CAPS may serve as a PI(4,5)P2-triggered switch for
dimerization. CAPS dimerizationmay be coupled to oligomeric
SNARE complex assembly for vesicle docking and priming.
In regulated exocytosis, vesicles fuse with the plasma mem-
brane in response to Ca2 elevations, releasing cargo such as
peptide hormones or neurotransmitters to the extracellular
space. CAPS3 (also known as CAPS-1, CADPS, and Unc-31p)
was discovered by its activity in promoting Ca2-triggered
dense core vesicle exocytosis in permeable neuroendocrine
cells (1, 2). Subsequent studies demonstrated the essential role
of CAPS in the docking and priming of dense core vesicles and
synaptic vesicles in endocrine and neural cells (3–14). CAPS
proteins contain at least three important functional domains
corresponding to the C2 domain, pleckstrin homology (PH)
domain, and Munc13 homology domain 1 (MHD1) (Fig. 6A)
(15). Based on sequence homology inC-terminal regions, CAPS
is a member of a CATCHR (complexes associated with tether-
ing containing helical rods) family of tethering/priming pro-
teins that operate at various stages in the secretory pathway
(16–18). Munc13-1/2 proteins in this family function similarly
to CAPS but non-redundantly at priming steps in vesicle exo-
cytosis (3, 7, 12, 19, 21).
The three annotated CAPS domains are important for activ-
ity in regulated vesicle exocytosis. The C2 domain of CAPS is
essential for nervous system function inCaenorhabditis elegans
indicated by the uncoordinated phenotype of unc-31(e714) and
unc-31(ox299) strains that harbor point mutations in the C2
domain of the conserved worm CAPS ortholog UNC-31p (22).
The exact role of the C2 domain in CAPS function was
unknown and is revealed in the current study. The adjacent PH
domain of CAPS has been characterized as a PI(4,5)P2-binding
domain required forCAPS activity in supporting regulated exo-
cytosis in cells and for enabling PI(4,5)P2- and SNARE-depen-
dent liposome fusion (4, 19, 23–25). The PH andC2 domains of
CAPS are closely adjacent (Fig. 6A) and could exhibit mutual
regulation as in other tandemdomain proteins (26). Last, CAPS
interacts with Q-SNAREs (syntaxin-1 and SNAP-25) and, at
lower affinity, with the R-SNARE (VAMP2) that comprise the
neuronal SNARE complex (27). SNARE binding by CAPS is
mediated by MHD1 or more C-terminal domains within the
CATCHR region (15, 28). Current models for function in vesi-
cle exocytosis suggest that CAPS on dense core vesicles (3)
engages PI(4,5)P2 andQ-SNAREs on the plasmamembrane via
its PH and MHD1 domains, respectively, to promote SNARE
complex assembly for vesicle docking and priming (17, 29).
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CAPS promotes the formation of dimers of SNARE com-
plexes on liposomes, but it was unclear whether this was medi-
ated by the dimerization of CAPS (23, 30). Early hydrodynamic
studies of partially purified protein suggested that CAPS was a
dimer (2). However, three protein bands were identified in
native gel electrophoresis of purified CAPS, but the oligomeri-
zation state of these CAPS forms was not established (31). Here
we report that purified soluble recombinant CAPS is in mono-
mer-dimer equilibrium favoring the monomer but that the
membrane-bound active formofCAPS is a dimer. PI(4,5)P2 and
Q-SNARE interactions stabilize the CAPS dimer. The role of
the CAPS C2 domain in mediating homodimerization was
revealed by studies of the mammalian counterparts of unc-31
C2 domain mutants (22) and a C2 domain deletion that exhibit
altered dimer formation and loss of function in vesicle exocy-
tosis. Last, analysis suggests that CAPS dimerizes similarly to
Munc13-1/2 using conserved homodimerization residues in its
C2 domain.
Results
Biochemical Characterization of CAPS Oligomerization—
We reported that native CAPS is a dimer, but this analysis was
conducted with partially purified protein using indirect hydro-
dynamic criteria (2). However, a reassessment of oligomeriza-
tion with a highly purified active recombinant CAPS-Myc-His
protein (32) indicated that the protein migrated in blue native
gel electrophoresis as a major 350-kDa and a minor 700 kDa
band (Fig. 1A). Treatment of the protein with SDS, which was
effective at disassembling oligomeric molecular mass stan-
dards, collapsed the 700-kDa but not the 350-kDa form of the
protein (Fig. 1B). This suggested that the 350 kDa band corre-
sponds to a monomer, whereas the 700-kDa band is an oli-
gomer. Consistent with this, zero length cross-linking partially
converted the CAPS-Myc-His monomer to an oligomer that
resisted SDS-induced disassembly (Fig. 1C). The minor
amounts (6%) of oligomer in CAPS-Myc-His (n 27) did not
differ significantly from that detected in native cytosolic CAPS
(n  11), indicating that epitope tags were not responsible for
oligomer formation (e.g. see Fig. 4C). The molecular mass of
CAPS-Myc-His on SDS-PAGE is 145 kDa, which indicates
that the 350-kDa CAPS-Myc-His form in blue native gels
migrates as a non-globular protein with an oblate shape. To
assess its native molecular mass independent of shape, purified
CAPS-Myc-His was analyzed by analytical equilibrium ultra-
centrifugation, which showed that the major species of soluble
CAPS-Myc-His is a 150-kDa monomer (Fig. 1D). Minor
amounts of a highermolecularweight oligomer(s)were notwell
resolved by this method.
Gel filtration studies indicated that the dominant form of
CAPS-Myc-His migrates with a Stokes radius (RS) of 59 Å
similar to a 350-kDa globular protein (Fig. 2A). This is con-
sistent with a moderately elongated 145-kDa monomer with
an RS/Rmin value of 1.7 (33). The 0.17 Kav monomer frac-
tions from gel filtration analyzed by native gels contained
ratios of monomer to oligomer similar to the input, indicat-
ing that gel-filtered monomer partially converts to oligomer
(Fig. 2A). Long exposure of the Western blot revealed oli-
gomer in the 0.06–0.12Kav fractions (Fig. 2B), but analysis of
these fractions 1 day later showed substantial conversion to
monomer (Fig. 2C). We conclude that soluble CAPS-Myc-
His is in dynamic monomer-oligomer equilibrium favoring
monomer.
Atomic Force and Single Molecule Microscopy—To further
assess the oligomerization state of CAPS, we employed
atomic force microscopy (AFM) and single-molecule
microscopy. AFMmeasures protein volume and can be used
to determine oligomer stoichiometry (34). The volume of
CAPS-Myc-His was measured after drying directly onto
mica or after it was added to a supported lipid bilayer (SLB)
on mica with or without PI(4,5)P2. The majority of CAPS-
Myc-His on mica (Fig. 3A) or on the SLB lacking PI(4,5)P2
(Fig. 3B, top) was monomer. However, the inclusion of
PI(4,5)P2 in SLBs strikingly enhanced the amount of CAPS-
Myc-His present as a dimer (Fig. 3B, bottom). The stimula-
tory effect of PI(4,5)P2 on CAPS-Myc-His oligomerization
was confirmed in native gel electrophoresis studies showing
that CAPS-Myc-His oligomerized upon incubation with
FIGURE 1. Soluble CAPS is predominantly monomeric. A, BN-PAGE (blue
native gel, 6–14%) of NativeMarkTM protein ladder and purified recombinant
CAPS-Myc-His, representative of eight similar analyses. B, Western blot
(-CAPS) from BN-PAGE of purified CAPS-Myc-His without or with 2% SDS
(left) and NativeMarkTM protein ladder without or with 2% SDS (right), repre-
sentative of three similar analyses. C, Western blot (-CAPS) of purified
CAPS-Myc-His fromCN-PAGE (clear native gel) without or with 2% SDS and
with 2% SDS following CAPS cross-linking with 0.5 mM 1-ethyl-3-(3-dim-
ethylaminopropyl) carbodiimide and 1.25 mM sulfo-NHS for 2 h at room
temperature, representative of two similar studies. Arrows, high mobility
CAPS-Myc-His monomer and lowmobility CAPS-Myc-His oligomer.D, sed-
imentation equilibrium data from analytical ultracentrifugation of CAPS.
Raw data (squares) are shown for three different speeds (3600 (blue), 6000
(green), and 8800 (red) rpm) with three different loading concentrations
for each speed. Fits (black lines) were derived from a non-interconverting
two-species model where the observed molecular weight/monomer molec-
ularweight for each species is1.0 and14, corresponding tomonomerand
higher molecular weight unresolved components, respectively.
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PI(4,5)P2 micelles (Fig. 3C). PI(4,5)P2 was the most effective
phosphoinositide for inducing oligomerization (Fig. 3D).
The results indicate that CAPS-Myc-His exists in two states
and that PI(4,5)P2 binding promotes the formation of oligo-
mers that correspond to dimers.
Single molecule microscopy can be used to determine oligo-
meric state by monitoring the number of photobleaching steps
for fluorescently tagged proteins (35). CAPS-mKate2-His mol-
ecules were held by His antibodies (Fig. 3E), and photobleach-
ing steps were monitored by total internal reflectance fluores-
cence (TIRF) microscopy (Fig. 3, F and G). As controls,
monomeric mKate2 was shown to exhibit one-step bleaching,
whereas dimeric mKate2 exhibited an increased number of
two-step bleaches (Fig. 3H). CAPS-mKate2-His mainly exhib-
ited 1-step bleaching, but5% of the molecules exhibited two-
step bleaching, indicating that a minor population of dimers is
present (Fig. 3H). The inclusion of PI(4,5)P2 markedly
enhanced dimerization of the CAPS-mKate2-His protein (Fig.
3H). To exclude the role of the His tag, we prepared a CAPS-
mKate2 protein, which exhibited similar PI(4,5)P2-enhanced
dimerization (Fig. 3H). Collectively, the AFM and single mole-
cule studies indicate that CAPS oligomers correspond to
dimers and that PI(4,5)P2 enhances CAPS dimerization.
CAPS Dimers Are Functional in Vesicle Exocytosis—To
determine the functional significance of the oligomeric states of
CAPS, we assessed whether there was a preferential association
of CAPSmonomer or dimer with PC12 cell membranes. CAPS
is a soluble cytosolic protein that partitions ontomembranes (3,
25, 36). PC12 cells were mechanically permeabilized and
washed to remove soluble contents (Fig. 4A (i)). Extensively
washed permeable cells retain small amounts of bound native
CAPS (4) that is efficiently extracted by a high salt wash (Fig.
4B) or by direct electrophoresis into native gels (not shown). In
contrast to native cytosolic CAPS, which was 5% dimer, the
extracted membrane-bound CAPS was entirely dimer as ana-
lyzed on native gels (Fig. 4C). Similar studieswere conducted by
adding purified CAPS-Myc-His to the permeable cells (Fig. 4A
(ii)). The addition of purified CAPS to permeable PC12 cells
stimulates Ca2-dependent dense core vesicle exocytosis (4,
31).We tested the activity of the added purifiedCAPS-Myc-His
and compared this with the activity of bound CAPS-Myc-His
after a wash to remove unbound CAPS-Myc-His (Fig. 4A (iii)).
CAPS-Myc-His bound to the permeable cells was exclusively
dimer (Fig. 4D) and exhibited 50% of the activity (Fig. 4E,
curve iii) of added CAPS-Myc-His (Fig. 4E, curve ii) in promot-
ingCa2-dependent secretion. Control studies showed that the
activity of bound CAPS-Myc-His was inhibited by neutralizing
CAPS antibodies but not by control IgGs (Fig. 4F). Strikingly,
the bound CAPS-Myc-His dimer represented only1% of the
input CAPS-Myc-His (Fig. 4D) but accounted for 40–60% of
the detected activity (Fig. 4E). The results indicate that dimer is
the active membrane-bound form of CAPS associated with
Ca2-triggered exocytosis.
Binding to SNARE proteins and PI(4,5)P2 is required for
CAPS activity in exocytosis (15, 19), so we assessed the oligo-
meric state of purified CAPS bound to liposomes containing
Q-SNAREs and PI(4,5)P2. The CAPS-Myc-His bound to
Q-SNARE-, PI(4,5)P2-containing liposomes purified by flota-
tion (Fig. 5A) exhibited increased dimer compared with input
(Fig. 5, B and C). CAPS-Myc-His dimers were not evident in
flotation studies with PC/PS-containing liposomes (Fig. 5, B
and C) or with liposomes containing only PI(4,5)P2 (Fig. 5C).
Although these results appeared to differ from theAFM studies
with PI(4,5)P2-containing SLBs (Fig. 3B), we attribute this to
the dissociation of CAPS-Myc-His during flotation when
bound at low affinity to PI(4,5)P2-containing liposomes. The
recovery of CAPS-Myc-His from liposomes containing only
Q-SNAREs was also low (Fig. 5C) but corresponds to the syn-
ergy between PI(4,5)P2 and Q-SNAREs for CAPS activity on
liposomes (23). Collectively, the results show that CAPS dimers
preferentially associate with PI(4,5)P2 and Q-SNAREs and that
FIGURE2.Oligomeric formsofCAPSare indynamic equilibrium.A, gel filtrationof CAPS-Myc-His detectedbyWesternblot of CN-PAGE. Input to the column
is indicated. The columnwas calibrated by the elution of aldolase, ferritin, and thyroglobulin. 0.16–0.19 Kav fractions correspond to CAPSmonomer. B, longer
exposure ofWestern blot of 0.06–0.12 Kav fractions to detect oligomer. Gel analysis was conducted immediately after gel filtration. C, Western blot of 0.11 and
0.12 Kav fractions kept on ice for 24 h after gel filtration. Purified oligomer partially dissociated tomonomer. Results shown are representative of two replicate
studies.
CAPS Functions as a Dimer
SEPTEMBER 30, 2016•VOLUME 291•NUMBER 40 JOURNAL OF BIOLOGICAL CHEMISTRY 21259
membrane-bound dimers are the functionally active form of
CAPS.
CAPS C2 Domain Mediates Dimerization—Additional evi-
dence for the importance of dimerization in CAPS activity and
for the role of the C2 domain in dimer formation was provided
by studies of CAPS C2 domain mutants. Mutant proteins
assessed were rat CAPS(G476E) and CAPS(L468K) plus vari-
ants (Fig. 6A) corresponding to the unc-31(e714) and unc-
31(ox299) alleles inC. elegans, respectively (22).We also gener-
ated a C2 domain deletion protein CAPS(C2). Mutant
proteins were purified asMyc-His fusion proteins and analyzed
by native gel electrophoresis to determine oligomerization state
(Fig. 6, B and C), and in the permeable PC12 cell assay to deter-
mine activity (Fig. 6E). The alleles at Leu-468 (L468E and
L468K) had significantly reduced dimer and exhibited loss of
function in the permeable cell assay (Fig. 6, B, C, and E). The
deletion construct CAPS(C2) also exhibited reduced
dimerization as well as reduced activity (Fig. 6, B,C, and E).We
FIGURE 3. CAPS oligomer is a dimer. A, atomic force microscopy volume analysis of purified CAPS dried onto mica (n 108). Representative images of AFM
field (left), representative images of single CAPS-Myc-His molecules (middle), and histograms of the CAPS-Myc-His volume distribution (right) are shown.
Volume data were fit to a double Gaussian with volumes of 109 nm3 for monomer and 264 nm3 for dimer. B, atomic force microscopy analysis of purified
CAPS-Myc-His added to SLB (top, n 448) or SLB containing PI(4,5)P2 (bottom, n 238) detectedmonomers at 94 nm
3 ormonomers at 115 nm3 plus dimer at
261 nm3, respectively. Inclusion of PI(4,5)P2 in SLBs significantly increased the amount of CAPS-Myc-His dimer (p  0.0001, Mann-Whitney-Wilcox test). C,
CAPS-Myc-His dimers increased upon PI(4,5)P2 addition as indicated by BN-PAGE of 5 g of CAPS-Myc-His incubated with 1.5 g of PI(4,5)P2 for 0–30 min.
Arrows, high mobility monomer and low mobility dimer. Results shown are representative of six experiments. D, incubations and analysis similar to C were
conductedwith the indicatedphospholipids showing thatCAPS-Myc-His dimerswerepreferentially induced (-fold increase is shown)byPI(4,5)P2 (meanS.D.
(error bars); *, p  0.001, n  5). E, pull-down of single CAPS-mKate2-His molecules. TIRF microscopy images showed puncta when CAPS-mKate2-His was
retained by His antibody (middle) but not with control antibody (right). Scale bar, 10 m. F, TIRF images (collected at 2 Hz) showing a one-step photobleach
event for immobilized CAPS-mKate2-His. Image size is 2.5  2.5 m. G, representative fluorescence intensity versus time analysis for 1-step and 2-step
photobleach events for CAPS-mKate2-His. H, percentages of puncta exhibiting two photobleaching steps were quantified for CAPS-mKate2-His tethered by
His antibodies (n 486), CAPS-mKate2-His bound to PI(4,5)P2 SLBs (n 296), CAPS-mKate2 (lackingHis tag) bound to PI(4,5)P2 SLBs (n 209), andmKate2-His
(n 307) or (mKate2)2-His (n 117) tethered by His antibodies. Note that the (mKate2)2-His dimer was only 50% pure and contaminated with fluorescent
monomeric mKate2. Values are mean S.D.
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also tested the CAPS(C2) protein with PI(4,5)P2 and found
that PI(4,5)P2-induced dimerization was similarly attenuated
(Fig. 6D).
Surprisingly, the CAPS(G476E) mutant exhibited strongly
increased oligomerization (Fig. 6,B andC) but was strongly loss
of function in the permeable cell assay (Fig. 6E). By contrast, a
CAPS(G476A) variant was similar to wild-type protein (data
not shown). Collectively, the data indicate that the C2 domain
of CAPS, previously of unknown function, is involved in CAPS
dimer formation and that altered dimerization inhibits CAPS
function.
C2 Domain Is Essential for CAPS Function in Cells—We
assessed the activity of the C2 domain mutants in regulated
dense core vesicle exocytosis in live PC12 cells (19). Cells
expressing brain-derived neurotrophic factor (BDNF)-EGFP as
vesicle cargo (Fig. 7A) were depolarized to promote Ca2
influx. Vesicle fusion eventswere detected by the brightening of
BDNF-EGFP in TIRF microscopy (Fig. 7B). The knockdown of
CAPS in PC12 cells with shRNA (	95% reduction in CAPS
(19)) strongly reduced Ca2-stimulated exocytosis (Fig. 7C).
Full rescue was achieved by expressing a CAPS-TagRFP con-
struct harboring silent mutations that bypass the shRNA (Fig.
7D). By contrast, CAPS(G476E), CAPS(C2), or CAPS(L468K)
FIGURE 4. CAPS dimer is the functional form of CAPS. A, PC12 cells were
passed through a ball homogenizer (10-m clearance) to tear the plasma
membrane and were washed in KGlu/BSA to remove cytosol (i). Purified
CAPS-Myc-His was added to 20 nM (ii), and cell ghosts were washed with
KGlu/BSA to remove unbound CAPS-Myc-His (iii). These three states were
assessed for activity in E. B, washed cell ghosts (i) were sequentially extracted
with 300 mM NaCl (high salt (HS)), 1% Triton X-100 (TX100), and SDS sample
buffer (SB) with boiling. Samples were analyzed by Western blotting from
SDS-PAGE with CAPS antibody. Results shown are representative of three
studies. C, cytosol from PC12 cells (left lane) was compared with HS extract of
endogenous CAPS from cell ghosts (i, right lane) in electrophoresis by CN-
PAGE andWestern blottingwith CAPS antibody. Results shown are represen-
tative of four studies.D, purified CAPS-Myc-His (1%of input shown)was com-
pared with 50% of HS extract from cell ghosts (iii) in electrophoresis by
CN-PAGE and Western blotting with Myc antibody. Results shown are repre-
sentative of two studies. Endogenous CAPS (C) or exogenous CAPS-Myc-His
(D) retained by PC12 cell ghosts migrated as dimer. E, Ca2-dependent nor-
epinephrine secretionwasmonitoredby rotatingdisk electrodevoltammetry
from cell ghosts indicated as i, ii, and iii in A. Ca2 was injected at zero time.
The results from three studies were averaged in the histogram (means S.E.
(error bars)); *, p 0.05. F, neutralizing CAPS antibodies inhibited the stimu-
lation of secretion by prebound CAPS (iii). Rabbit IgGs (-rabbit) were used as
the control for CAPS antibodies (-CAPS). Results shown are representative of
two studies.
FIGURE 5. CAPS dimers are enriched on liposomes containing Q-SNAREs
andPI(4,5)P2.A, diagramof flotation assay to separatebound fromunbound
CAPS-Myc-His in liposome binding studies. B, BN-PAGEWestern blot of input
(left), bound (right), and unbound (bottom) CAPS-Myc-His after flotation with
either protein-free (PF) or PI(4,5)P2- and Q-SNARE-containing liposomes.
Liposomes contained PC/PI(4,5)P2 (95:5). Results shown are representative of
two studies. C, BN-PAGE Western blot of bound CAPS-Myc-His after flotation
with either protein-free liposomes composed of PC/PS (85:15) or PC/PI(4,5)P2
(95:5) or Q-SNARE-containing liposomes with the same lipid compositions as
indicated. Liposomes were also extracted into 1% Triton X-100 to ensure
complete removal of bound CAPS-Myc-His. Results shown are representative
of two studies.
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proteins all failed to rescue Ca2-stimulated exocytosis (Fig. 7,
D–F) despite normal expression (Fig. 8). Intriguingly,
CAPS(G476E) expression also strongly reduced the number of
dense core vesicles visible in the TIRF field, whereas expression
of other mutants did not (data not shown). To determine
whether reduced exocytosis with CAPS(G476E) expression
(Fig. 7D) was solely attributable to the reduced number of ves-
icles in the TIRF field, the data were replotted as the number of
fusion events normalized to the number of vesicles in the TIRF
field. CAPS(G476E) was confirmed as strong loss of function
for exocytosis as were the CAPS(L468K) and C2 CAPS
mutants (Fig. 7G). The live cell studies agree with the permea-
FIGURE 6. Loss of function CAPSmutants exhibit altered dimerization. A,
domain architecture for R. norvegicus CAPS (NP_037351.1). C2 and PH
domains were identified bymultiple alignments in the SMART database. The
MHD1 domain is from Ref. 25. The DCV binding domain is from Ref. 57. Ser
phosphorylation (P) is from Ref. 31. CATCHR homology (boldface underline) is
from Ref. 20. B, loss of function C2 domainmutants of CAPS exhibit abnormal
dimerization. 100 ng of purified wild-type CAPS-Myc-His and mutants were
analyzed by CN-PAGE and visualized byWestern blot withMyc antibody. The
CAPS-Myc-His band corresponding to dephosphorylated CAPS (Dephos) (31)
was not routinely resolved from monomer in other CN-PAGE studies. C, the
percentage of dimer for each protein indicated below each lane in B is plotted
as histograms showing means  S.E. (error bars) for the indicated n values.
Comparisons with wild-type protein are indicated (**, p  0.0001). D, wild-
type CAPS-Myc-His and CAPS(C2)-Myc-His were tested for dimerization in
the absence (
) or presence () of PI(4,5)P2 as in Fig. 3C by BN-PAGE (**, p
0.001; n  3). E, activities of purified CAPS and mutants in a permeable cell
secretion assay tested at 20 nM in triplicate (mean  S.E.; **, p  0.0001).
Wild-type CAPS activity was set to 100%.
FIGURE 7. C2 domain mutants exhibit reduced activity in dense core
vesicle exocytosis. A, representative TIRF image of PC12 cell expressing
BDNF-GFP. Scale bar, 10 m. B, fluorescence intensity changes for a single
vesicle fusion event. Vesicle fluorescence is evident in the TIRF field before
fusion (1); fluorescence increases at the time of fusion pore opening (2);
and fluorescence subsequently decreases due to reacidification of the
cavicaptured vesicle (3). The width of each image in the montage is 1.5
m. C, exocytosis was evoked by depolarization with the addition of 56
mM KCl buffer at zero time. Curves indicate cumulative number of fusion
events per cell. CAPS knockdown significantly impaired secretion com-
pared with control cells (mean S.E. (error bars), n 14).D, rescue studies
in CAPS knockdown cells for CAPS-TagRFP (n  14) or CAPS(G476E)-
TagRFP (n 11). E, similar to D for rescue studies with CAPS-TagRFP (n
14) or CAPS(C2)-TagRFP (n  15). F, similar to D for rescue studies with
CAPS-TagRFP (n  14) or CAPS(L468K)-TagRFP (n  15). The similar
expression of CAPS proteins was confirmed by fluorescence of CAPS-
TagRFP constructs. Significant differences are indicated: **, p  0.001; *,
p  0.05. G, summary of CAPS C2 domain mutants compared with wild-
type CAPS. Fusion events per cell were normalized to the number of ves-
icles visible in the TIRF field (mean  S.E.; *, p  0.05; **, p  0.001).
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ble cell activity assay results (Fig. 6E) and further indicate the
essential nature of the C2 domain for CAPS function in vesicle
exocytosis.
CAPS(G476E) Cluster Dense Core Vesicles—CAPS in PC12
cells is cytoplasmic as well as bound to dense core vesicles (3).
CAPS(G476E) was loss of function for vesicle exocytosis (Fig. 7,
D and G) but also interfered with the transit of vesicles to the
plasma membrane. To further assess this, we determined the
localization of CAPS(G476E) in cells by confocal microscopy.
Expression of wild-type CAPS-EGFP or CAPS-TagRFP re-
sulted in a global cytoplasmic distribution that largely obscured
the dense core vesicle localization previously shown by TIRF
microscopy (3) (Fig. 8,A andB). CAPS(L468K) andCAPS(C2)
proteinswere expressedwell and localized similarly to thewild-
type protein as cytoplasmic. In striking contrast, CAPS(G476E)
localized to large structures within the cells (Fig. 8, A and C)
that also contained dense core vesicle proteins synaptotag-
min-1 and chromogranin B but not Golgi proteins TGN-38 or
syntaxin-6 (Fig. 8C). This suggested that CAPS(G476E) expres-
sion induced the cytoplasmic clustering of mature dense core
vesicles. We confirmed this by electron microscopy, which
revealed cytoplasmic clusters of intact dense core vesicles in
cells expressing CAPS(G476E) (Fig. 8D).
Vesicle clustering by CAPS(G476E) may be due to its
increased oligomerization (Fig. 6B) coupled with its binding to
dense core vesicles (Fig. 8F). CAPS binding to dense core vesi-
cles requires a C-terminal domain (Fig. 6A) (3, 25). We con-
structed a C-terminally truncated version of CAPS(G476E) and
found that vesicle clustering was eliminated (Fig. 8E). The
results indicate that the G476E mutation enhances CAPS self-
interactions even in trans across vesicle membranes. Such
results are consistent with a role for the C2 domain in CAPS
dimerization (Fig. 8F).
Bioinformatic Analysis of CAPS C2 Domain—Dimerization
may be mediated by homotypic interactions between C2
domains. Structures of C2 domain homodimers have been
reported for C2B of RIM1, C2B of Rgp3, and C2A of
Munc13-1 (37, 38). Analysis of these structures reveals several
conserved patterns for C2 homodimer formation. Residues
involved in dimerization, while uniquely positioned on each
structure, are in the same -strands. These residues interact
with residues on other  strands or with loops that connect the
 strands. Each of the three structures contains an electrostatic
lysine-aspartate interaction stabilized by interaction with an
aromatic residue and by a hydrogen bond from a third residue
(see below). We determined whether any of these dimerization
residues were conserved in CAPS by conducting C2 domain
alignments with Cn3D, which supplements traditional se-
quence alignment methods with structural data (39).
FIGURE 8. Localization of CAPSC2domainmutants in PC12 cells.A, representative confocal images of PC12 cells expressingwild-type ormutant CAPS-GFP
fusion proteins. Wild-type CAPS and CAPS(L468K) are broadly distributed in the cytoplasm, whereas CAPS(G476E)-GFP localizes to large structures. Scale bar,
10 m. B, confocal images of live PC12 cells expressing BDNF-GFP (vesicle cargo) and either wild-type CAPS, CAPS(C2), or CAPS(L468K) as TagRFP fusions.
Scale bar, 10 m. C, confocal images of fixed PC12 cells expressing CAPS(G476E)-GFP and immunostained for dense core vesicle proteins synaptotagmin-1
(Syt1) or chromogranin B (CgB), for trans-Golgi protein TGN-38, or for Golgi and immature vesicle protein syntaxin-6 (Syn-6). Scale bar, 15 m. D, electron
micrograph of fixed PC12 cell expressing CAPS-GFP or CAPS(G476E)-GFP. An enlarged region containing clusters of dense core vesicles is shown. Scale bar, 200
nm. Clusteringwas determined by the number of additional vesicles in a 400-nm radius surrounding a vesicle; binning results for 0–1 or2 vesicles/circle are
shown. CAPS(G476E)-GFP (n 7 sections) significantly increased the percentage of vesicleswith2 adjacent vesicles (**, p 0.001) comparedwith CAPS-GFP
(n  8 sections). Error bars indicate S.D. E, CAPS(G476E) clustering of dense core vesicles is dependent on the vesicle binding domain of CAPS. C-terminal
truncation of 135 residues fromCAPS abolished vesicle clustering by CAPS(G476E). Scale bar, 15m. F, model of dense core vesicle clustering by CAPS(G476E)
depicting C2 domain self-interactions and C-terminal vesicle-binding domain.
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Alignments revealed that residues involved in Munc13-1
C2A homodimerization are conserved in the CAPS C2 domain
(Fig. 9A). Specifically, two types of interactions are conserved.
Both C2 domains exhibit a characteristic partial chelation of a
charged residue by three residues on the opposing domain and
exhibit a lysine-glutamate electrostatic interaction (Fig. 9A).
The positions of these latter residues are flipped betweenCAPS
C2 and Munc13-1 C2A, which could function to prevent
CAPS-Munc13-1 heterodimer formation. To test the sequence
alignment predictions, we generated two charge reversal
mutants in the CAPS C2 domain that are predicted to reduce
dimerization. In accord with prediction, CAPS(K428D) and
CAPS(D472K) exhibited impaired dimerization (Fig. 9, B and
C). Importantly, both CAPS C2 domain mutants showed
reduced activity in the permeable PC12 cell assay (Fig. 9D). We
suggest that themechanismofC2 domain homodimerization is
conserved between the CAPS C2 domain and the Munc13-1
C2A domain.
Discussion
Essential Role of CAPS C2 Domain—We provide evidence
that the C2 domain is essential for CAPS activity as a regulator
of vesicle exocytosis. This conclusion initially emerged from
sequencing the unc-31(e714) and unc-31(ox299) loss of func-
tion alleles in C. elegans that correspond to rat CAPS(G476E)
and CAPS(L468K), respectively (22). These single point muta-
tions in the CAPS C2 domain are separated by seven residues.
Studies of regulated dense core vesicle exocytosis (Figs. 6 and 7)
showed that CAPS(G476E) was entirely inactive, whereas
CAPS(L468K) was partially active. Importantly, CAPS(C2)
exhibited no activity (Figs. 6 and 7). The results strongly indi-
cate that the C2 domain is required for CAPS activity in Ca2-
dependent dense core vesicle exocytosis.
The CAPS C2 domain lacks the canonical array of five aspar-
tate residues characteristic of Ca2-dependent, PS-binding C2
domains (40). We were unable to demonstrate Ca2-depen-
dent PS binding for CAPS C2 domain constructs that we have
FIGURE 9. Identifying conserved homodimerization motifs in Munc13-1 C2A and CAPS C2. A, sequence alignment of C2 domains generated by Cn3D. A
spatially conserved residue alignment for C2domainswas createdwith 97publishedC2 structures. This templatewas used to compareMunc13-1C2A (Protein
Data Bank code 2CJT), CAPS RN (R. norvegicus, NP_037351), CAPS MM (Mus musculus, NP_036191), CAPS HS (Homo sapiens, Q9ULU8), CAPS DM (Drosophila
melanogaster, AAN06591), and CAPS CE (C. elegans, NP_001255666) sequences. Boldface type indicates residues that are spatially conserved across all 97
structures. Red and blue, partial chelation of a charged residue (lysine, blue) by 3 opposing residues (red) is conserved for Munc13-1 and CAPS. Green,
electrostatic interaction between a lysine and glutamine is conserved spatially, although the residue positions are inverted between CAPS and Munc13-1.
Orange, Munc13-1 homodimer interactions that involve residues with variable spatial positioning between C2 domains. Yellow, Leu-468 and Gly-476 residues
identified in CAPS (22), where mutation causes loss of function. B, charge reversal mutations (K428D and D472K) in residues conserved in Munc13-1 C2A and
CAPS C2 domains impair CAPS dimerization. Similar amounts of the indicated proteins were analyzed by CN-PAGE andWestern blotting with CAPS antibody.
C, data fromBwerequantitated, indicatingdecreaseddimerization in K428DandD472Kproteins comparedwithwild type (*,p0.05,mean S.D. (error bars),
n 3).D, CAPS(K428D) and CAPS(D472K) proteinswere tested at 20 nM in the permeable cell secretion assay and found to be significantly impaired compared
with wild-type CAPS (*, p 0.05, mean S.D., n 3).
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produced. However, C2 domains in proteins also mediate pro-
tein-protein interactions (38, 41–47). C2 domains can also
homodimerize, such as in piccolo, dysferlin, RIM1a,Munc13-1,
and Rgp3 (38, 48–50). That the CAPS C2 domain mediates
homodimerization is suggested by the findings thatmonomeric
CAPS in solution is in dynamic equilibriumwith a pool of dimer
and that a large number of C2 domain mutant CAPS proteins
(L468E, L468A, L468K, K428D, D472K, and C2) exhibit
strong reductions in dimerization. It is unlikely that these
mutant CAPS proteins are either globally or locally misfolded
because they express at wild-type levels in cells, bind PI(4,5)P2
similarly towild-typeCAPS, and exhibit similar patterns of lim-
ited proteolysis.4 It is likely that these mutant proteins exhibit
reduced affinity for C2 domain self-interactions.
The CAPS(G476E) mutant corresponding to the unc-
31(e714) allele has unusual properties that nonetheless sup-
port the idea of C2 domain-mediated oligomerization.
CAPS(G476E) is strongly loss of function at the level of vesicle
exocytosis (Figs. 6 and 7), and it also clusters dense core vesicles
in the cytoplasm of cells (Fig. 8). We interpret this to indicate
that the G476E C2 domain gains affinity for self-interaction so
that it dimerizes in trans across membranes (Fig. 8F). Indeed,
CAPS(G476E) exhibits a very strong tendency to oligomerize as
dimers as well as possible tetramers (Fig. 6B). We cannot elim-
inate the possibility that the C2 domain in this mutant is locally
misfolded by substitution of a small uncharged side chain by a
charged side chain. The G476A allele, by contrast, exhibited
wild-type properties. Gly-476 is highly conserved in CAPS and
in other C2 domains (Fig. 9A), residing near the beginning of a
flexible linker that connects two  strands. Whether the Gly to
Glu substitution promotes local unfolding of the C2 domain or
introduces additional electrostatic interactions is unclear, but
the G476E substitution appears to strongly enhance C2-C2
domain interactions.
That both decreased (e.g. CAPS(C2) and CAPS(L468K)) as
well as increased (e.g.CAPS(G476E)) dimerization result in loss
of CAPS function suggests that a cycle of dimerization and its
reversal plays a role in CAPS function. CAPS dimerization may
need to be locally activated with correct timing such that pre-
mature dimerization inhibits activity. Consistent with this,
complete dephosphorylation inactivates CAPS and shifts it
toward an oligomeric state (31). It should be noted that the
current work reassigns the speculated dimer-tetramer equilib-
rium of that previous study (31) to a monomer-dimer
equilibrium.
Distinct Roles for Dimerization in CAPS and Munc13-1
Function—CAPS andMunc13-1 proteins comprise a subgroup
of CATCHR family proteins exhibiting 40% sequence simi-
larity in a 500-residue region that is C-terminal to the C2
domain of CAPS. Dimerization of the Munc13-1 protein has
not been directly determined but is proposed based on C2A-
C2A dimer structures (38). Mutations that disrupt C2A-C2A
dimers (K32E) were found to enhance Munc13-1 function in
neurons, suggesting that Munc13-1 monomers are active (50).
A proposed mechanism for Munc13-1 activation involves
RIM1-induced dissociation of C2A-C2A dimers to activate
Munc13-1 as a monomer (38, 50). This contrasts with our
results for CAPS, which indicate that C2 domain-mediated
dimerization is required for function in vesicle exocytosis. The
monomer-dimer equilibrium strongly favoring monomer for
CAPS indicates that the affinity for self-interaction between
soluble CAPS monomers is low, which contrasts with the
reported high affinity for Munc13-1 C2A-C2A interactions
(38).
Although CAPS and Munc13-1 are each proposed to pro-
mote the assembly of SNARE complexes for vesicle priming,
the two proteins function distinctively and non-redundantly (3,
7, 12, 19, 21). CAPS promotes the formation of dimers of het-
erotrimeric SNARE complexes on liposomes, which may be
mediated by multivalent interactions of an active membrane
dimer of CAPS with SNARE proteins (30). This is similar to
mechanisms suggested for a number of dimeric tethering fac-
tors (51, 52). By contrast, Munc13-1 is suggested to open a
closed form of syntaxin-1 (53), which may be well suited for an
active monomeric Munc13-1 protein.
Despite divergent roles for dimerization in function, the
mechanism of dimerization for CAPS and Munc13-1 may be
similar. Munc13-1 C2A and CAPS C2 domains exhibit 41%
amino acid sequence similarity, and neither is a Ca2-depen-
dent phospholipid-binding domain (50). Conserved residues in
the CAPS C2 domain (Lys-428 and Asp-472) were identified
based on the Munc13-1 C2A homodimer structure (38).
Charge reversal mutations in these residues impaired CAPS
dimerization and function, supporting the conclusion that
dimerization mechanisms for CAPS and Munc13-1 are
conserved.
Regulation of CAPS Dimer Formation and Function—The
binding of PI(4,5)P2 to CAPSmarkedly enhanced dimer forma-
tion (Fig. 3). Binding of PI(4,5)P2 to the PH domain of CAPS
(25) may induce dimer formation by synergistic interactions
within the central C2-PH region of CAPS (Fig. 6A). The PH
domain is immediately adjacent to the C2 domain so that bind-
ing of PI(4,5)P2 in the membrane could drive C2 domain-me-
diated dimerization. PH domains can also dimerize (54, 55),
which could account for the incomplete loss of dimerization in
CAPS(C2). Dimerization of the PH domain in CAPS could
increase the avidity for binding PI(4,5)P2, which would further
stabilize dimers on the membrane. More C-terminal domains
in dimerized CAPS such as MHD1 might in turn exhibit mul-
tivalent interactions with SNARE proteins to promote the
assembly of dimers of SNARE complexes, as observed on lipo-
somes (30). Thus, the unique central C2-PH domain of CAPS
could serve as an important PI(4,5)P2-dependent switch for the
activation of CAPS as a dimer onmembrane. Thismodel would
account for the essential roles for PI(4,5)P2 binding and
dimerization in CAPS function.
Experimental Procedures
DNA Constructs—A site-directed mutagenesis kit (Qiagen,
Hilden, Germany) was used with pcDNA3.1 CAPS-Myc-His
(Rattus norvegicus) as the template to introduce L468A, L468E,
L468K, G476A, G476E, K428D, or D472K single point muta-
tions. For the C2-CAPS, overlap extension PCR was used to4 M. Petrie, unpublished observations.
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delete amino acids 400–516 from the CAPSORF. This allowed
residue 399 to be directly fused to residue 517 without





CAPS-mKATE2-His constructs were created by cutting CAPS-
Myc-His from pcDNA3.1 with XhoI and AfeI and ligating into
a similarly cut mKate2-C (Evrogen, Moscow, Russia) appended
with a C-terminal His purification tag. All constructs were con-
firmed by Sanger sequencing.
Protein Purification—For purification of CAPS-Myc-His and
CAPS-mKate2-His, CAPS was transfected into HEK293-FT
(Invitrogen) cells using a standard calcium phosphate protocol.
Two days after transfection, cells were washed and removed
with PBS. Cells were resuspended in 0.5% Triton X-100, 20 mM
HEPES, 300 mM NaCl, 5 mM imidazole (IDA) with protease
inhibitors andpelleted to remove cell debris. Supernatantswere
loaded onto a nickel-nitrilotriacetic acid column (Qiagen),
washed, and eluted with 20 mM HEPES, 300 mM NaCl, 200 mM
IDA. Eluates were diluted with 20 mM HEPES to 20 mM NaCl,
100 mM NaCl and concentrated to10 M CAPS.
Blue and Clear Native PAGE—For clear native PAGE, puri-
fied CAPS-Myc-His and mutants in 20 mM HEPES, 10 mM
NaCl, 10mM imidazole, 5% glycerol, pH 7.4, were loaded onto a
6% polyacrylamide gel without SDS or DTT. Gels were run at
150 V for 2 h at 4 ºC. For immunodetection, native gels were
subjected to a standard blotting protocol. Blue native PAGE
was performed as described previously (56). Briefly, 5–14%
acrylamide resolving gels were poured with a 3.3% acrylamide
stacking gel (Buchler Instruments, Fort Lee, NJ). Protein sam-
ples were mixed with 2 sample buffer (0.25% Coomassie
G250, 75 mM BisTris, 10% glycerol, 1.5 M 6-aminocaproic acid,
pH 7.0) and directly loaded into the gel. Gels were run at 150 V
through the stack and then turned up to 250V for 2 h.Gels were
fixed in 40% methanol, 30% acetic acid, 2.5% glycerol followed
by Coomassie G250 staining or subjected to immunoblotting.
Western blotting was conducted with polyclonal antibodies
generated against purified full-length rat CAPS or with Myc
monoclonal 9E11 (Covance, Dedham, MA).
Analytical Ultracentrifugation—Three different CAPS con-
centrations (0.2–8.4 M) were analyzed.100 l of each sam-
ple was loaded into sectors of 1.2-cm charcoal-filled epon cen-
terpieces with 110 l of the final dialysate buffer in the
reference sector. Data were collected at 4 °C with the gradients
monitored at 279 nm. From the CAPS sequence, the partial
specific volume was 0.733 ml/g and is uncorrected for temper-
ature. The buffer composition was 100 mM NaCl, 1 mM EDTA
in HEPES buffer at pH 7.4. The density at 4 °C was 1.0044 g/ml,
as calculated from density increments (Laue diffraction) and
corrected to 4 (no increment was available for HEPES, and its
contribution was neglected). CAPS molecular mass was com-
puted as 150,613. An extinction coefficient of 138,660/M/cm
was used based on Pace’s average extinction (58) and does not
include the disulfide bonds. Equilibrium data were collected at
3600, 6000, and 8800 rpm. Equilibriumwas assumed when gra-
dients collected 3 h apart were superimposable. After a high
speed spin for a few hours depleted all protein material, the
remaining absorbance in the low field region was taken as a
measure of non-sedimentable absorbance, which was 0.01
and treated as fixed during various model fittings. The range of
absorbance in the data included in the analysis ranged from
0.03 to 1.4 (at 1.2-cm path length) or a concentration of 0.2–8.4
M. For data shown (Fig. 1D), the three lines for each color
represent different rotor speeds for the high (green), medium
(blue), and low (red) loading concentration.
Atomic Force Microscopy—CAPS was imaged by adding 100
pM CAPS to freshly cleaved mica disks and allowed to dry or
imaged submerged with SLBs at 10 nM. 1,2-Dioleoyl-sn-
glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-
phospho-L-serine (DOPS), and 1,2-dioleoyl-sn-glycero-
3-phospho-(1-myo-inositol-4,5-bisphosphate) (PI(4,5)P2),
obtained from Avanti Polar Lipids (Birmingham, AL) as chlo-
roform stocks, weremixed atmolar ratios of 75% phosphatidyl-
choline, 25% phosphatidylserine or 75% phosphatidylcholine,
22% phosphatidylserine, 3% PI(4,5)P2. Chloroform was evapo-
rated under a streamof nitrogen, and the lipidswere rehydrated
overnight in water (MilliQ) at a lipid concentration of 2 mg/ml.
The lipid suspensionwas incubated at 65 °C for 30min and then
cooled to room temperature. CAPS, NaCl, HEPES-NaOH, and
CaCl2were added to produce a liposome suspension containing
10 nM CAPS in HEPES-buffered saline (HBS; 100 mM NaCl, 20
mMHEPES, pH 7.6) and 1mMCaCl2. The suspensionwas incu-
bated at 37 °C for 30 min and then deposited onto freshly
cleaved mica disks (Agar Scientific, Stansted, UK). After a
3-min adsorption, the sample was rinsed with HBS containing
CaCl2 to remove unadsorbed liposomes and transferred to the
atomic force microscope. AFM imaging was carried out at
room temperature using a Bruker Multimode atomic force
microscope equipped with an E-scanner and a Nanoscope IIIa
controller, with an in-line electronics extendermodule (Bruker,
Coventry, UK). All images were collected using tapping mode
in fluid with Micromasch AFM cantilevers NSC18/AL BS
MikroMasch (Innovative Solutions Bulgaria Ltd., Sofia, Bul-
garia). The cantilevers (typically exhibiting a spring constant of
2.8 newtons/m) were tuned to 10–20% below the peak of the
resonance frequency, generally between 25 and 35 kHz. The
drive amplitude was set to generate a root mean square ampli-
tude of 2 V. Themicroscopewas engagedwith a 0-nm scan area
to allow for tuning. The set point was applied to the sample.
Images (2 2m)were captured at a scan rate of 2Hz andwith
512 scan lines/area. Data analysis was performed using com-
mercially available software (NanoScope III, Digital Instru-
ments) or with ImageJ. Multiple images were taken from one
supported lipid bilayer for each condition.
Single Molecule Microscopy—Single molecules of CAPS-
mKate2-His, mKate2-His, or the dimeric (mKate2)2-His were
immobilized on glass by SiMPull (35). Briefly, an imaging
chamber was created by sandwiching 24 60-mm number 1.5
and 22 60-mm number 1.5 glass slides between lines of high
vacuum grease to create 4–5 channels with a volume between
20 and 50 l. Chambers were rinsed with 10 chamber volumes
of buffer (25 mM HEPES, 100 mM KCl, pH 7.4) to remove dust
and aBSA/antibody solution (FCprotein (10mg/ml),monoclo-
nal His tag antibody (Penta-His (Qiagen)) concentration of 0.1
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mg/ml), incubated for 10 min, and flushed with 5 chamber vol-
umes of buffer, and 50 pM CAPS-mKate2-His was added to the
chamber; protein was diluted in prelubricated 1.7-ml Eppen-
dorf tubes to minimize nonspecific absorption to the plastic
surface (Costar, catalog no. 3207). Alternatively, CAPS-
mKate2-His was immobilized on 5% PI(4,5)P2-containing
SLBs. CAPS-mKate2 lacking the His tag was prepared by cleav-
age with tobacco etch virus protease (R&D Systems, Minneap-
olis, MN) and similarly bound to SLBs. Unbound protein was
removed with 5 chamber volumes of buffer, and the bound
protein was imaged by TIRF microscopy on a TE2000 inverted
scope (Nikon) stationed on a floating table. A 514-nm laser line
excited the fluorophore and was imaged with an Evolve digital
monochrome EMCCD camera (Photometrics, Tucson, AZ).
500-frame movies with a capture rate of 2 Hz were recorded.
Movies were drift-corrected using the ImageJ plugin Descrip-
tor-based registration (2d/3dt); movies with significant drift
were discarded.Movies were processed via aMatlab script gen-
erously provided by Dr. Aaron Hoskins (University of Wiscon-
sin, Madison, WI). Photobleaching steps were manually
recorded if a spotmaintained uniform fluorescence before pho-
tobleaching, did not display x,y-drift, and underwent photo-
bleaching in one frame.
Gel Filtration—Gel filtration of purified CAPS-Myc-His was
conducted on a Sephacryl-300 (Amersham Biosciences, Little
Chalfont, UK) prepacked column via FPLC. The column was
calibrated by monitoring the elutions of thyroglobulin (670
kDa), ferritin (440 kDa), and aldolase (158 kDa). PurifiedCAPS-
Myc-His was loaded onto the column, and 72 1.2-ml fractions
were collected and analyzed by clear native gels and
immunoblotting.
Cell Ghost Binding—PC12 cells were washed twice with PBS,
removed with KGlu/BSA buffer (120 mM potassium glutamate,
20mMpotassium acetate, 20mMHEPES, 2mMEGTA, 1mg/ml
BSA, pH 7.2), and passed once through a ball homogenizer
(10-mclearance). 100mM EGTAwas added to a final concen-
tration of 10mM, and permeable cells were incubated on ice for
30–60 min and washed with KGlu/BSA to remove cytosolic
proteins. Cell ghosts were divided into Eppendorf tubes, resus-
pended in 20nMCAPS-Myc-His in priming solution (Mg-ATP/
rat brain cytosol) for 12 min at 30 °C, and washed two times in
1 ml of KGlu/BSA. Bound CAPS was either extracted with 300
mM NaCl (high salt) or loaded directly onto native gels. 50%
glycerol was added to a final concentration of 5% before loading
onto native gels.
Liposome-binding Assays—Proteoliposomes were prepared
by co-micellization as described previously (23). Briefly, syn-
taxin-1/SNAP-25 in 25mMHEPES, pH 7.4, 100mMKCl, 50mM
IDA, 1% -octyl glucoside was used to resuspend a dried film of
2.5 mM lipid of DOPC, 5% PI(4,5)P2. After resuspension, mix-
tures were rapidly diluted into 25 mMHEPES, 100 mM KCl, pH
7.4; dialyzed overnight into 25 mM HEPES, 100 mM KCl, 1 mM
DTT, pH 7.4, with 1 g/liter Biobeads; and purified on an Accu-
denz medium (Accurate Chemical Corp., Westbury, NY) gra-
dient. Liposomes were made identically with the omission of
the SNARE proteins. The addition of 3H-labeled 1,2-dipalmi-
toyl phosphatidylcholine to liposomes was used to monitor
lipid recovery, and SDS-PAGE densitometry of the Q-SNAREs
was used to assess protein content. 1 M CAPS-Myc-His was
incubated with Q-SNARE proteoliposomes for 30 min at room
temperature. Reactionsweremixed 1:1with 80%Accudenz and
pipetted into a thin walled polycarbonate tube, overlaid with
30% Accudenz and a 20 mM HEPES, 100 mM KCl, pH 7.4, layer
for centrifugation (45000 rpm, SW50 swinging bucket rotor).
Floated fractions were withdrawn and analyzed by either blue
native or SDS-PAGE. For blue native analysis where indicated,
Triton X-100 was added to a final concentration of 0.5% for
severalminutes followed by 2 blue native PAGE buffer (0.25%
Coomassie G250, 75 mM BisTris, 10% glycerol, 1.5 M 6-amino-
caproic acid, pH 7.0) for 5 min. When quantification was
required, floated fractions were monitored by the total amount
of 3H-labeled 1,2-dipalmitoyl phosphatidylcholine.
Permeable Cell Secretion Assay—Rotating disc electrode vol-
tammetry was used to detect norepinephrine secretion from
PC12 cell ghosts as described previously (4) using PC12 cells
loaded overnight with 1.5 mM norepinephrine, 0.5 mM ascor-
bate. Cell ghosts were prepared as described above, washed in
KGlu/BSA, and incubated in priming solution (rat brain cytosol
at 1:10 dilution and 2 mM Mg-ATP) for 12 min at 30 °C, which
generates PI(4,5)P2 on the plasma membrane, washed, and
resuspended in KGlu/BSA. Cell ghosts were added directly to
the rotating disc electrode chamber with 10 nM CAPS, and
Ca2 was injected. A rotating carbon disc electrode with an
applied potential of500MVdetected norepinephrine release.
The output was processed by a Dataq analog to digital data
acquisition system and analyzed by WinDaq software.
Live PC12 Secretion Assay—The Ca2-dependent exocytosis
of BDNF-GFP-containing vesicles from live PC12 cells was
monitored by TIRF microscopy as described previously (19).
Briefly, PC12 cells were transfected with BDNF-GFP, a CAPS
shRNA plasmid, and a CAPS-mKate2 construct and plated on
MatTek glass bottom dishes. After 48 h, cells were imaged by
TIRF on aNikon TE2000-Umicroscope. Resting cells in 15mM
HEPES, pH 7.4, 145 mM NaCl, 5.6 mM KCl, 2.2 mM CaCl2, 0.5
mM MgCl2, 5.6 mM glucose, 0.5 mM ascorbic acid, 0.1% BSA
were stimulated by buffer exchange into 15mMHEPES, pH 7.4,
95 mMNaCl, 56 mM KCl, 2.2 mM CaCl2, 0.5 mMMgCl2, 5.6 mM
glucose, 0.5 mM ascorbic acid, 0.1% BSA. GFP fluorescence was
excited with a 488-nm laser, and mKate2 fluorescence was
excited with a 514-nm laser and imaged at 4 Hz with either a
CoolSNAP-ES digital monochrome CCD camera (Photomet-
rics, Tucson, AZ) or an Evolve digital monochrome EMCCD
camera (Photometrics) and analyzed by ImageJ software. Exo-
cytic events were scored manually.
Confocal and Electron Microscopy—PC12 cells were trans-
fected with an Electroporator II instrument (Invitrogen) and
plated on glass coverslips, and 48 h later, cells were fixed with
4% formaldehyde plus PBS for 20min at room temperature. For
immunostaining, fixed cells were extracted in 0.1% Triton
X-100. Cells were washed with PBS and blocked for 30 min in
10% BSA plus PBS. Fixed cells were incubated with primary
antibody for 1 h, washed, and incubated with secondary anti-
body for 1 h. After washes in PBS, cells were mounted and
imaged on a Nikon C1 confocal microscope (TE2000-U). Pri-
mary antibodies usedwere chromogranin Bmonoclonal gener-
ously provided by W. B. Huttner (Max Planck Institute of
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Molecular Cell Biology and Genetics, Dresden, Germany),
TGN38monoclonal generously provided by K. E. Howell (Uni-
versity of Colorado, Denver, CO), syntaxin 6 monoclonal anti-
body (catalog no. 610636, BD Biosciences), and synaptotag-
min-1 N-terminal polyclonal antibody (Sigma-Aldrich). For
electron microscopy, PC12 cells were transfected with pCMV
CAPS-GFP or CAPS(G476E)-GFP for 48 h, sorted by FACS on
a SORP BD FACSAria (University of Wisconsin Carbone Can-
cer Center Flow Cytometry Laboratory) to remove untrans-
fected cells, and fixed. Cells on glass coverslips were fixed in a
solution of 2.5% glutaraldehyde, 2.0% paraformaldehyde in 0.1
M sodium phosphate buffer (PB), pH 7.4, for 1 h at room
temperature. Samples were rinsed 5 times for 5min in 0.1 M PB.
The rinsed cultureswere post-fixed in 1%osmium tetroxide, 1%
potassium ferrocyanide in PB for 1 h at room temperature. The
samples were rinsed in PB followed by distilled water rinses
three times for 5min each to clear phosphates. Sampleswere en
bloc stained in saturated aqueous uranyl acetate for 2 h at room
temperature and rinsed in distilled water three times for 5 min
each. Dehydration was performed at room temperature in a
graded ethanol series (35, 50, 70, 80, and 90% for 5min, 95% for
10 min, 100% three times for 10 min) and transitioned in pro-
pylene oxide two times for 7 min each. Durcupan ACM (Fluka
AG, Buchs, Switzerland) resin was used during infiltration and
embedding. Increasing concentrations of accelerated (10 ml of
A/M, 10 ml of B, 300 l of C, 100 l of D components) Durcu-
pan were used for infiltration. All infiltration steps were done
with the coverslips, cell side up, in aluminumweighing dishes in
covered glass Petri dishes to minimize evaporation. The cul-
tures were embedded in open aluminum weighing dishes at
60 °C in a drying oven overnight until polymerized. Samples
were floated in concentrated hydrofluoric acid, glass side down,
for 15 min to etch off the glass, revealing the embedded cells.
Sections were viewed with a Philips CM120 transmission elec-
tron microscope, and images were documented with a Mega-
View III (Olympus-SIS, Lakewood, CO) side-mounted digital
camera.
Sequence Alignments—We used the C2 domain conserved
protein domain family (CD00030) as a seed for C2 domain
alignments. It is produced by an automated algorithm, which
employs generic search parameters that invariably contain
omissions and misalignments that require refinement. Only 32
of 97 C2 domain structures represented in the C2 domain
PFAM (PF00168) were included (at the time of submission, this
PFAM has 105 structures). The missing structures were
imported into Cn3D and aligned with the provided block align-
ment algorithm. The sequence alignment of every structure was
manually refinedbyassessing the resulting spatial overlapbetween
the C2 domain in question with all other C2 structures. After
assessing every strand for all structures, we were able to create a
sequence alignment for all C2domain structures that is based on a
highdegreeof spatial overlapbetweenallC2domain residues.The
aligned residues represent the core C2 domain residues that have
an invariant spatial positioning between these 97 crystal struc-
tures. Using these core C2 residues as a search query, DALI iden-
tified all other C2 domain structures in the C2 PFAM, yielding an
average rootmean square deviation of 1Å that accounts for 100 of
the residues tested for spatial overlap. It is common to observe
backbone atoms of two aligned C2 domains in these conserved
regions with distances between 0.4 and 0.6 Å, less than that of an
H–H bond.
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